Aurinia 制药 AUPH
$16.46 +$0.25 (+1.54%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $16.46 0.00%
开盘$16.25
昨收$16.21
当日区间$16.16 – $16.57
成交量1.28M
市值$2.21B
市盈率（TTM）7.2
股息率–
AUPH 相关新闻
匹配 Aurinia Pharmaceuticals 或代码 AUPH 的头条新闻，按最新排序。
- Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M
- TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
- Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 正面
- Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock
- Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20
- Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
- Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
- Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
- RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
- H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
- Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q3 EPS $0.23, Vs. FactSet Est of $0.22
- Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, Vs. FactSet Est of $83.6M
- TR | OpenAI - 4o Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $13 正面
- TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
- H.C. Wainwright Initiates Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Announces Target Price $17
暂无评论——快来第一个聊聊 AUPH。